Immunological memory is the ability of the adaptive immune system to ensure a persistent protective effect after immunization. However, it can also be a limitation to building a sufficient level of protective antibodies specific to new mutations of the virus. It is imperative to bear this phenomenon (called "original antigenic sin") in mind and make every effort to overcome its inherent pitfalls when updating current and designing new vaccines.

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Anesthesia and Intensive Medicine 1st Faculty of Medicine Charles University and University Military Hospital Prague Czech Republic

Department of Epidemiology and Biostatistics Charles University 3rd Faculty of Medicine Prague Czech Republic

Zobrazit více v PubMed

JANSSEN BIOTECH, INC . COVID-19 vaccine Ad26.COV2.S VAC31518 (JNJ-78436735). Vaccines and related biological products advisory committee meeting; Meeting date: 2021. February 26. [accessed 2021 March 15]. https://www.fda.gov/media/146219/download.

AstraZeneca . COVID-19 vaccine AstraZeneca. Assessment report. Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000; [accessed 2021 March 15]. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf.

Francis T, Davenport FM, Hennessy AV.. A serological recapitulation of human infection with different strains of influenza virus. Trans Assoc Am Physicians. 1953;66:231–3. PubMed

Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya JM, Gershwin ME. Original antigenic sin: a comprehensive review. J Autoimmun. 2017;83:12–21. doi:10.1016/j.jaut.2017.04.008. PubMed DOI

Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009; 58:521–24. PubMed

Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature. 1991;354:389–92. doi:10.1038/354389a0. PubMed DOI

Wisseman CL, Sweet BH, Kitaoka M, Tamiya T. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg. 1962;11:550–61. doi:10.4269/ajtmh.1962.11.550. PubMed DOI

Masurel N, Ophof P, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond). 1981;87:201–09. doi:10.1017/s0022172400069412. PubMed DOI PMC

Chakradhar S. Updated, augmented vaccines compete with original antigenic sin. Nat Med. 2015;21:540–41. doi:10.1038/nm0615-540. PubMed DOI

Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384. doi:10.1371/journal.pone.0004384. PubMed DOI PMC

Park MS, Kim JI, Park S, Lee I, Park MS. Original antigenic sin response to RNA viruses and antiviral immunity. Immune Netw. 2016;16:261–70. doi:10.4110/in.2016.16.5.261. PubMed DOI PMC

Holzmann H, Kundi M, Stiasny K, Clement J, McKenna P, Kunz C, Heinz FX. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol. 1996;48:102–07. doi:10.1002/(sici)1096-9071(199601)48:1<102::Aid-jmv16>3.0.Co;2-i. PubMed DOI

Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch Gesamte Virusforsch. 1973;43:315–19. doi:10.1007/bf01556147. PubMed DOI

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. doi:10.1056/NEJMc2032195. PubMed DOI PMC

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594–99. doi:10.1038/s41586-020-2814-7. PubMed DOI

Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz G, Ali M, Koralov SB, et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv [Preprint]. 2021. Feb 9. doi:10.1101/2021.02.07.21251311. PMID: 33594383; PMCID: PMC7885942. PubMed DOI